Evidence map›Paper›PMID 24707137›Full record

ReviewWorld journal of gastroenterology2014

Anemia in inflammatory bowel disease: a neglected issue with relevant effects.

Danila Guagnozzi, Alfredo J Lucendo

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.

  1. Guideline
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Observational
  10. Review
  11. Review
  12. Article
  13. Nutritional Global Status and Its Impact in Crohn's Disease.Journal of the Canadian Association of Gastroenterology · 2021
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Inflammatory bowel disease and restless leg syndrome.Neurosciences (Riyadh, Saudi Arabia) · 2020
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Danila GuagnozziDanila Guagnozzi, Alfredo J Lucendo, Department of Gastroenterology, Hospital General de Tomelloso, 13700 Tomelloso, Ciudad Real, Spain.
Alfredo J LucendoDanila Guagnozzi, Alfredo J Lucendo, Department of Gastroenterology, Hospital General de Tomelloso, 13700 Tomelloso, Ciudad Real, Spain.
Hospital General de Tomelloso · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anemia, a common complication associated with inflammatory bowel disease (IBD), is frequently overlooked in the management of IBD patients. Unfortunately, it represents one of the major causes of both decreased quality of life and increased hospital admissions among this population. Anemia in IBD is pathogenically complex, with several factors contributing to its development. While iron deficiency is the most common cause, vitamin B12 and folic acid deficiencies, along with the effects of pro-inflammatory cytokines, hemolysis, drug therapies, and myelosuppression, have also been identified as the underlying etiology in a number of patients. Each of these etiological factors thus needs to be identified and corrected in order to effectively manage anemia in IBD. Because the diagnosis of anemia in IBD often presents a challenge, combinations of several hematimetric and biochemical parameters should be used. Recent studies underscore the importance of determining the ferritin index and hepcidin levels in order to distinguish between iron deficiency anemia, anemia due to chronic disease, or mixed anemia in IBD patients. With regard to treatment, the newly introduced intravenous iron formulations have several advantages over orally-administered iron compounds in treating iron deficiency in IBD. In special situations, erythropoietin supplementation and biological therapies should be considered. In conclusion, the management of anemia is a complex aspect of treating IBD patients, one that significantly influences the prognosis of the disease. As a consequence, its correction should be considered a specific, first-line therapeutic goal in the management of these patients.

Indexed as

AnemiaAnemia, Iron-DeficiencyCytokinesDietary SupplementsErythropoietinFerritinsFolic Acid DeficiencyHemolysisHepcidinsHumansInflammatory Bowel DiseasesIronPrognosisQuality of LifeVitamin B 12 DeficiencyCytokinesErythropoietinFerritinsHepcidinsIronAnemiaAnemia of chronic diseaseErythropoietinInflammatory bowel diseaseIron deficiency

Identifiers

PMID24707137
PMCPMC3974521
OpenAlexW2074822449

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.